Activity and toxicity of docetaxel (Taxotere®) in women with previously treated metastatic breast cancer

Australian and New Zealand Journal of Medicine

Volumn 27, Issue 1, 1997, Pages 40-44

  Shapiro, J D ^a   Millward, M J ^a   Rischin, D ^a   Davison, J D ^a   Michael, M ^a   Francis, P A ^a   Ganju, V ^a   Toner, G C ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Docetaxel (Taxotere ); Metastatic breast cancer

Indexed keywords

ANTINEOPLASTIC AGENT; DEXAMETHASONE; DOCETAXEL;

ADULT; AGED; ALOPECIA; ARTICLE; ASCITES; BREAST CANCER; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; EDEMA; FEMALE; FLUID RETENTION; HUMAN; HYPERSENSITIVITY; INTRAVENOUS DRUG ADMINISTRATION; METASTASIS; NAIL DYSTROPHY; NAUSEA; NEUROPATHY; NEUTROPENIA; RASH; VOMITING;

EID: 0030932650     PISSN: 00048291     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-5994.1997.tb00912.x     Document Type: Article

References (20)

1. Jelfs P, Giles G, Shugg D et al. (Eds). Australian Institute of Health and Welfare: Cancer in Australia 1986-1988. Canberra: Australian Government Publishing Service, 1994.
2. Henderson IC. Chemotherapy for advanced disease. In: Harris JR, Hellman S, Henderson IC et al. (Eds). Breast diseases. Philadelphia: JB Uppincott, 1987; 428-79.
3. Coates A, Gebski V, Bishop JF et al. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl J Med 1987; 317: 1490-5.
4. Walters RS, Frye D, Buzdar AU et al. A randomized trial of two dosage schedules of mitomycin C in advanced breast carcinoma. Cancer 1992; 69: 476-81.
5. Millward MJ, Hendrick A, Cantwell BMJ. Fixed dose short course mitomycin C with vincristine in advanced pre-treated breast cancer. Ann Oncol 1990; 1: 373-4.
6. Rowinsky EK, Donehower RC. Drug therapy: Paclitaxel (Taxol). NEnglJMed 1995; 15: 1004-14.
7. Phillips KA, Friedlander M, Olver I et al. Australasian multicentre phase II study of paclitaxel in relapsed ovarian cancer. Aust NZ J Med 1995; 25: 337-43.
8. Cortes JE, Pazdur R. Docetaxel. J Clin Oncol 1995; 13: 2643-55.
9. Verweij J, Clavel M, Chevalier B. Paclitaxel and docetaxel: Not simply two of a kind. Ann Oncol 1994; 5: 495-505.
10. Common Toxicity Criteria, Cancer Therapy Evaluation Program, Division of Cancer Treatment, National Cancer Institute, Bethesda, Md, USA.
11. Miller AB, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
12. Huinink WW, Prove AM, Piccart M et al. A phase II trial of docetaxel in second line treatment with chemotherapy for advanced breast cancer. Ann Oncol 1994; 5: 527-32.
13. Valero V, Holmes FA, Walters RS et al. Phase II trial of docetaxel: A new, highly effective antineoplastic agent in the management of patients with anthracyclineresistant metastatic breast cancer. J Clin Oncol 1995; 13: 2886-94.
14. Ravdin PM, Burns HA, Cook G et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 1995; 13: 2879-85.
15. Taguchi T, Adachi I, Enomoto K et al. Docetaxel in advanced or recurrent breast cancer. Early and late Phase II clinical trials in Japan. Proc Am Soc Clin Oncol 1994; 13: 87 (Abstr. 152).
16. Seidman AD, Reichman BS, Crown JPA et al. Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol 1995; 13: 1152-9.
17. Gelmon K, Nabholtz JM, Bontenbal M. Randomised trial of two doses of paclitaxel in metastatic breast cancer after failure of standard therapy. Ann Oncol 1994; 5 (Suppl 5): 198 (Abstr. 493).
18. Abrams JS, Vena DA, Baltz J et al. Paclitaxel activity in heavily pretreated breast cancer: A National Cancer Institute Treatment Referral Center trial. J Clin Oncol 1995; 13: 2056-65.
19. Wilson WH, Berg S, Bryant G et al. Paclitaxel in doxorubicin-refractory or mitoxantrone refractory breast cancer: A phase I/II trial of 96-hour infusion. J Clin Oncol 1994; 12: 1621-9.
20. Eisenhauer EA. Docetaxel: Current status and future prospects. J Clin Oncol 1995; 13: 2865-8.